UROMITEXAN 200MG INJECTION 2ML
₹31.5*
MRP ₹35
10% off
₹30*
MRP ₹35
15% CB
₹5 cashback(15%)
Free Delivery
With Circle membership
(Inclusive of all Taxes)
This offer price is valid on orders above ₹800. Apply coupon PHARMA10/PHARMA18 (excluding restricted items)
Provide Delivery Location
UROMITEXAN 200MG INJECTION 2ML belongs to a class of medication known as 'cytoprotectant' primarily used to prevent Hemorrhagic cystitis (a condition that causes bleeding in the urine due to the effect of anticancer agents (Ifosfamide). Our bodies degrade the anticancer drug (ifosfamide) to generate a compound (acrolein) that can injure and irritate the bladder. UROMITEXAN 200MG INJECTION 2ML decreases the risk of bladder irritation and bleeding caused by other anti-cancer drugs.
UROMITEXAN 200MG INJECTION 2ML contains 'Mesna', a chemo-protectant medicine that alters the breakdown of anti-cancer agents (Ifosfamide) found in the urine, making it less toxic. In addition, it binds to other urotoxic metabolites and inhibits their effects on the bladder.
UROMITEXAN 200MG INJECTION 2ML will be administered to your vein by a trained healthcare professional; hence, do not self-administer. In some cases, this medicine may cause certain side effects such as nausea, vomiting, headache, flushing (sense of warmth in the face, ears, neck, and trunk), lethargy, rash, diarrhea, light-headedness, abdominal pain, flu-like symptoms, fever, and injection site reactions. Most of these side effects do not require medical attention and gradually resolve over time. However, if the side effects are persistent, reach out to your doctor.
UROMITEXAN 200MG INJECTION 2ML is not recommended if you are allergic to it or any of its ingredients. An effective birth control measure should be taken to avoid pregnancy in women of a mother-bearing you’re your doctor may suggest regular urine and blood test while receiving UROMITEXAN 200MG INJECTION 2ML to monitor your CBC (blood cell count). UROMITEXAN 200MG INJECTION 2ML is not indicated for use in hematuria due to other underlying pathological conditions like thrombocytopenia. It is advised to drink at least 1-2 litres of fluid daily while receiving UROMITEXAN 200MG INJECTION 2ML. This medicine should be avoided in pregnant and breastfeeding populations due to serious side effects; hence inform your doctor before administration.
UROMITEXAN 200MG INJECTION 2ML belongs to a class of medication known as 'chemoprotectant' primarily used to prevent bleeding into the urine by a particular anticancer medicine known as ifosfamide (ifosfamide-induced hemorrhagic cystitis). It also reduces the risk of inflammation and bleeding in the bladder by receiving anti-cancer medication. It contains Mesna, which works by reacting chemically with the urotoxic ifosfamide (anti-cancer medicines) metabolites, resulting in their detoxification. In addition, it binds to other urotoxic metabolites and inhibits their effects on the bladder.
Do not take this injection if you are allergic to UROMITEXAN 200MG INJECTION 2ML or any of its ingredients. An effective birth control method should be used to avoid pregnancy in women of childbearing age. Maintain a three-month gap between your last dose of UROMITEXAN 200MG INJECTION 2ML and your next pregnancy. Regular urine and blood test should be done while receiving UROMITEXAN 200MG INJECTION 2ML to monitor your CBC (blood cell count). It is not indicated for use in hematuria due to other underlying pathological conditions like thrombocytopenia. This medicine is known to cause blurry vision and dizziness, so do not drive or operate machinery.
Drug-Disease Interactions: UROMITEXAN 200MG INJECTION 2ML is known to interact in patients with an autoimmune disorder like rheumatoid arthritis (pain and inflammation in the joints), systemic lupus erythematosus (a severe form of lupus in which pain and fatigue occur in joints), or nephritis (a type of kidney problem).
Drug-Food Interactions: Inform your doctor about all vitamins, minerals you are taking.
Drug-Drug Interactions: UROMITEXAN 200MG INJECTION 2ML is known to interact with anticoagulants (anisindione, dicumarol, warfarin).
Ifosfamide-induced Hemorrhagic cystitis: It is a condition that causes bleeding in the urine due to the effect of anticancer agents (Ifosfamide). It occurs when an individual undergoes planned chemotherapy (for cancer treatment). During chemotherapy, an anticancer medication called 'ifosfamide' causes inflammation and bleeding of the bladder, which is passed into the urine. The colour of urine may vary from pink to red in colour.
Alcohol
Caution
Avoid consumption of alcohol while on treatment with UROMITEXAN 200MG INJECTION 2ML as it may lead to serious side effects.
Pregnancy
Unsafe
UROMITEXAN 200MG INJECTION 2ML is not recommended to be used in pregnancy as it may cause serious side effects. Use effective birth control measures before starting the treatment with Ifosamide and for 3 months after completing the treatment. If you get pregnant while you are receiving UROMITEXAN 200MG INJECTION 2ML, inform your doctor.
Breast Feeding
Unsafe
UROMITEXAN 200MG INJECTION 2ML should not be used if you are breastfeeding as it is known to pass through the breast milk and harm your infant. Do not breastfeed for at least one week following your last dosage of mesna or ifosfamide.
Driving
Unsafe
UROMITEXAN 200MG INJECTION 2ML is known to cause blurred vision and drowsiness. So, do not drive or operate machinery, which requires mental alertness.
Liver
Caution
Let your doctor know if you have any history of liver diseases before receiving UROMITEXAN 200MG INJECTION 2ML.
Kidney
Caution
Let your doctor know if you have any history of kidney diseases before receiving UROMITEXAN 200MG INJECTION 2ML. Your doctor may adjust the dose or prescribe a suitable alternative based on your condition.
Children
Caution
The safety and efficacy of UROMITEXAN 200MG INJECTION 2ML in children have not been established. Moreover, UROMITEXAN 200MG INJECTION 2ML contains benzyl alcohol, which is known to cause a gasping syndrome in children. Hence, use is not recommended.
Country of origin
Manufacturer/Marketer address
Product Substitutes